CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced upcoming presentations to be made at the 31st Annual FSHD Society International Research Congress being held June 13-14, 2024 in Denver, Colorado, including an abstract outlining the baseline characteristics of patients enrolled in the Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD). The presentations to be made are as follows:
Presentation Date and Time: Thursday, June 13, 2024, between 5:30-8:30 PM MDT
Presentation Number: S6.06
Format: Oral presentation
Presentation Date and Time: Friday, June 14, 2024 at 3:50 PM MDT
Title: Safety and Tolerability of Losmapimod for the Treatment of FSHD First Author: Mihaela Levitchi Benea, MD, Executive Director of Medical Affairs at Fulcrum Therapeutics Presentation Date and Time: Thursday, June 13, 2024, between 5:30-8:30 PM MDT
Title: Reliability and Validity of Reachable Workspace Total Score with Wrist Weights in
First Author: Lena Hubig, Acaster Lloyd Consulting
Presentation Date and Time: Thursday, June 13, 2024, between 5:30-8:30 PM MDT
The presentation and posters will be available on the publications page of Fulcrum’s website at https://www.fulcrumtx.com. Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule in development for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and pociredir, a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD) and other hemoglobinopathies. Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn. ccalabrese@lifesciadvisors.com